News headlines about Qiagen (NASDAQ:QGEN) have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Qiagen earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.0572092834052 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Qiagen (QGEN) traded up $0.41 during trading on Friday, reaching $34.21. 1,008,936 shares of the company traded hands, compared to its average volume of 1,416,368. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $7,800.00, a PE ratio of 201.24, a PEG ratio of 1.93 and a beta of 1.03. Qiagen has a 1-year low of $27.74 and a 1-year high of $36.34.
Qiagen declared that its board has authorized a share buyback plan on Wednesday, January 31st that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.
QGEN has been the topic of several analyst reports. TheStreet upgraded shares of Qiagen from a “c+” rating to a “b+” rating in a report on Tuesday, November 7th. Deutsche Bank restated a “buy” rating on shares of Qiagen in a report on Friday, December 1st. Commerzbank restated a “buy” rating on shares of Qiagen in a report on Tuesday, December 12th. Goldman Sachs Group initiated coverage on shares of Qiagen in a report on Monday, January 29th. They set a “buy” rating and a $39.00 price target on the stock. Finally, Cowen restated a “hold” rating and set a $34.00 price target on shares of Qiagen in a report on Thursday, December 21st. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $35.33.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://ledgergazette.com/2018/02/17/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-qiagen-qgen-share-price.html.
Qiagen Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.